TipRanks
Advertisement
Advertisement

IMUX Stock Latest News

Unchanged $56 Target as Slutsky Reiterates Buy on IMUX, Highlighting Vidofludimus Calcium’s Dual Mechanism and Safety Advantage in MS
RatingsUnchanged $56 Target as Slutsky Reiterates Buy on IMUX, Highlighting Vidofludimus Calcium’s Dual Mechanism and Safety Advantage in MS
9d ago
IMUX
Immunic Highlights Multiple Sclerosis Program in R&D Webinar
PremiumCompany Announcements
Immunic Highlights Multiple Sclerosis Program in R&D Webinar
11d ago
8K
IMUX
Analyst Reiterates Buy on Immunic, Sees Undervalued MS Opportunity with Unchanged $56 Price Target
PremiumRatings
Analyst Reiterates Buy on Immunic, Sees Undervalued MS Opportunity with Unchanged $56 Price Target
19d ago
IMUX
Immunic price target raised to $29 from $19 at Roth Capital
PremiumThe Fly
Immunic price target raised to $29 from $19 at Roth Capital
19d ago
IMUX
Immunic appoints Chitrang Dave as chief data, digital officer
PremiumThe Fly
Immunic appoints Chitrang Dave as chief data, digital officer
19d ago
IMUX
Immunic initiated with an Outperform at Wedbush
PremiumThe FlyImmunic initiated with an Outperform at Wedbush
1M ago
IMUX
Immunic: Buy Rating Reiterated as Analyst Highlights Multiple Sclerosis Milestones and Maintains $22 Price Target
Premium
Ratings
Immunic: Buy Rating Reiterated as Analyst Highlights Multiple Sclerosis Milestones and Maintains $22 Price Target
1M ago
IMUX
Sam Slutsky Initiates Buy on Immunic, Citing Late-Stage MS Program, Expansion into Progressive MS, and Strengthened Nurr1-Focused Pipeline
Premium
Ratings
Sam Slutsky Initiates Buy on Immunic, Citing Late-Stage MS Program, Expansion into Progressive MS, and Strengthened Nurr1-Focused Pipeline
1M ago
IMUX
Immunic Adds Veteran Finance Leader to Board
PremiumCompany Announcements
Immunic Adds Veteran Finance Leader to Board
1M ago
8K
IMUX
Immunic reports Q2 EPS (80c), consensus ($1.16)
PremiumThe Fly
Immunic reports Q2 EPS (80c), consensus ($1.16)
1M ago
IMUX
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial
PremiumTipRanks Newswire
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives FDA Clearance to Advance Lucid-MS Into Phase 2 Multiple Sclerosis Trial
1M ago
IMUX
QNTM
IMUX Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
IMUX Upcoming Earnings Report: What to Expect?
2M ago
IMUX
Immunic Updates Corporate Strategy, Highlights Vidofludimus Plans
PremiumCompany AnnouncementsImmunic Updates Corporate Strategy, Highlights Vidofludimus Plans
2M ago
8K
IMUX
Immunic Names CEO Erik Lundgren to Board
Premium
Company Announcements
Immunic Names CEO Erik Lundgren to Board
3M ago
8K
IMUX
Immunic Expands Equity Plan and Reelects Board Directors
Premium
Company Announcements
Immunic Expands Equity Plan and Reelects Board Directors
3M ago
8K
IMUX
Immunic Highlights Positive Phase 2 CALLIPER MS Data
PremiumCompany Announcements
Immunic Highlights Positive Phase 2 CALLIPER MS Data
4M ago
8K
IMUX
Immunic Appoints New CEO to Lead MS Strategy
PremiumCompany Announcements
Immunic Appoints New CEO to Lead MS Strategy
4M ago
8K
IMUX
Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed
PremiumThe Fly
Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed
4M ago
IMUX
B. Riley cuts Immunic target, sees ‘compelling entry point’
PremiumThe Fly
B. Riley cuts Immunic target, sees ‘compelling entry point’
4M ago
IMUX
Immunic Appoints Michael Bonney as Board Chair
PremiumCompany AnnouncementsImmunic Appoints Michael Bonney as Board Chair
4M ago
8K
IMUX
Immunic appoints Michael Bonney as chair
Premium
The Fly
Immunic appoints Michael Bonney as chair
4M ago
BIIB
IMUX
Immunic price target lowered to $19 from $26 at Roth Capital
Premium
The Fly
Immunic price target lowered to $19 from $26 at Roth Capital
4M ago
IMUX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >